- HanchorBio has entered a strategic collaboration with WuXi Biologics to support the development and GMP manufacturing of multiple fusion protein programmes.
- The agreement covers end-to-end biologics services to accelerate clinical development and enable scalable global manufacturing.
HanchorBio, Inc. has signed a strategic collaboration agreement with WuXi Biologics to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programmes from its pipeline. The collaboration is focused on advancing assets derived from HanchorBio’s Fc-Based Designer Biologics (FBDB™) platform for oncology and autoimmune indications.
Under the agreement, WuXi Biologics will provide integrated, end-to-end biologics development and manufacturing services. These include cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The partnership is intended to accelerate clinical translation, improve CMC execution efficiency, and support scalable global development through contract manufacturing and CDMO services.
The collaboration aligns with HanchorBio’s strategy to progress multiple platform-derived assets from early clinical stages towards commercialisation with development speed and manufacturing robustness. By leveraging WuXi Biologics’ global quality systems and experience in complex biologics, HanchorBio aims to maintain flexibility across several clinical programmes.
WuXi Biologics will apply its proprietary technology platforms, including the WuXia™ TrueSite targeted integration-based CHO cell line platform and the WuXiHigh™ high-throughput formulation development platform, to support speed, quality, and scalability across the programmes.
“This partnership with WuXi Biologics strengthens our ability to translate platform-driven innovation into high-quality clinical and commercial assets. As we advance multiple next-generation fusion protein programs, execution speed, manufacturing reliability, and scalability are critical.”
Scott Liu, Founder, Chairman, and Chief Executive Officer of HanchorBio
